Group items tagged

With the government gearing up and pushing community pharmacies in England to adopt the hub and spoke dispensing model, stakeholders of the sector and industry leaders analyse the pros and cons related to the new concept. The model rose to prominence in 2015 in community pharmacy and the medicine supply chain in the UK, and has undergone a few consultations and reviews at the professional and governmental level since then. From a broader perspective, the industry agrees that the model will bring in efficiency to the system, much needed amid community pharmacy's flat funding settlement in England, at the same time highlighting some real challenges. The National Pharmacy Association (NPA) has so far released three reports on this matter and a review of the challenges and enablers of the hub and spoke in the UK in 2016. Besides, a review of international evidence and the report of a roundtable meeting was brought together in the supply chain with government and regulators in early 2020.

Digital pharmacy app Charac has raised over £1 million in debt and equity, bringing total funding to date for the London-based startup to £2.5m. Pharmacy Business understands while the majority of the new finance, worth about £1.2 million, comes from the National Pharmacy Association (NPA) coffer, the remainder is put forward by a number of individual pharmacy businesses. The pharmacy sector is in a state of crisis, experiencing nearly two closures per week over the past two years, Charac said in a statement. According to data from the NHS Business Services Authority, there are now only 11,026 community pharmacies in England, the lowest number since 2015. The current crisis is attributed to escalating operational costs, a shortage of staff, and diminished government financial support.

Today, pharmaceutical companies can't simply make an effective drug and count on healthcare providers (HCPs) to come to them - they have to find innovative ways to attract them. Statista shows that in 2015 there were only 3,286 pharma companies with active research and development pipelines. In 2023, this number jumped to more than 5,500. As an earth-shattering number of new drugs are flooding the market each year, HCPs are having a hard time determining the best medicine for their patients. Meanwhile, pharma companies invest more in marketing to help HCPs get rid of choice paralysis and make them choose their solution over that of competitors. In this article, we will share the tried-and-true tactics to build a strong pharma brand. Get creative with interactive email marketing One…two…three…No, we're not counting to run a marathon. Three seconds is what you've got to pull your reader in with your email. Fail to quickly grab the audience's attention? We've got some bad news for you. Nobody's going to bother reading about how amazing your pharmaceutical product is if you're churning out generic emails with artificial intelligence tools.

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority's (CMA) findings against two pharmaceutical manufacturers who consistently overcharged hydrocortisone tablets for over a decade. Auden/Actavis UK's pricing for the critical medicine 'hydrocortisone' from 2008 to 2018 constituted an abuse of their dominant market position, leading to fines nearing £130 million, CMA said in a statement. "These companies increased the price of this crucial medicine by over 10,000 per cent, soaring from 70p to £72 within that period. These are the highest ever CMA penalties upheld by the Tribunal," the CMA said. In July 2021, the CMA imposed fines exceeding £265 million on hydrocortisone manufacturers Auden Mckenzie and Actavis UK, which acquired Auden's business in 2015 and subsequently became Accord-UK. The fines were imposed for abuse of dominance and collusion by both the parent companies and potential competitors. The recent verdict, announced on September 18, comes five weeks after the Tribunal supported the CMA's decision in a separate case regarding the pricing of medicines supplied to the NHS. In that prior case, fines amounted to £84 million.

Dr Thérèse Coffey, the MP for Suffolk Coastal, has been appointed as health secretary - the fourth person to get the job after Jeremy Hunt, Matt Hancock, Sajid Javid and Steve Barclay in the past five years. She replaces Steve Barclay who held the job for just two months between July and September. Having first been elected in 2010 and subsequently re-elected in 2015, 2017 and 2019, Dr Coffey has served as secretary of state for the Department of Work and Pensions. Previous to that she served as environment minister, deputy leader of the House, government whip and parliamentary private secretary. As an MP she has campaigned on improving NHS experience for patients. Dr Coffey grew up in the North West and has a PhD in Chemistry and a chartered management accountant qualification.

Pharmacies have administered more than five million flu vaccinations under the national flu vaccination service in 2022/23, revealed the advanced service flu report published by the NHS Business Services Authority (NHSBSA). According to the report, 5,007,578 million vaccinations has been administered by community pharmacies in 2022/23. Whilst in 2021/22 the total number of vaccines administered in community pharmacies was 4.85 million. The service has continued to achieve year-on-year growth in the number of vaccinations administered since it launched in 2015. Commenting on the end-of-season figures, Alastair Buxton, Director of NHS Services, Community Pharmacy England said: "This season's flu vaccination figures are yet another example of the incredible contribution that our members and their teams make to protect the public and the NHS as part of a key public health programme. "Given the significant financial and workforce pressures that our members continue to face, this year on year growth is a fantastic achievement and a testament to their hard work and dedication.

Community pharmacies are located within the very hotspots of peoples' communities, yet a staggering 720 individual businesses have stopped trading since 2015. It has been called a "national disgrace and a betrayal to the elderly and the vulnerable" by sector leaders. The funding crisis has been compounded by a gruelling 18-24 months post-Covid, both have which have placed immense pressure on the retail pharmacy sector. The population is aging and with this comes patients living with a range of long-term health conditions. Medication regimes are becoming ever more complex and as a result, maintaining prescription and medication adherence services is challenging to say the least. Yet the public feel great warmth towards their local pharmacy businesses, and this positive attitude only increased during the pandemic. In fact, in a recent report launched by Omnicell on the Changing Role of the Pharmacist, a survey of public opinion found that a third (32 per cent) said they perception of their local pharmacy had changed for the better since the start of the pandemic and nearly half (44 per cent) said they are more familiar with their local pharmacy services since the start of COVID. This has meant that the role of the pharmacist has also changed and evolved; in part due to a national need and drive for more patients to be seen and supported clinically by pharmacists. This change of service provider role has slowly been developing over the last couple of years. Pharmacists are currently carrying out 65 million consultations a year - a staggering rise of 44 per cent in the last 24 months alone.

Labour MP Barry Gardiner has raised concerns that the £645 million cash injection announced by the government for community pharmacy is, in effect, 'frozen funding' for the next two years. Speaking on Tuesday (May 9) on the BBC's Politics Live, Gardiner said funding for community pharmacies "was cut before 2015, then it was frozen and now the latest announcement says that it's going to be frozen for a further two years." He said with a current national contract, which already represented a 25 per cent funding cut in real terms, it was not appropriate to ask for community pharmacy "to take on more work" without adequate support. "I heard the prime minister earlier this morning (May 9) on TV saying 'we are investing more in pharmacies'. "No you are not. You just concluded a contract that says for the next two years it will be absolutely flatlined." He added that "there will be no more money" for community pharmacy and that steeply rising costs due to inflation were "eating into that contract's health". Gardiner said community pharmacists "do a phenomenal job" but regretted that from a total of just 11,000, some 700 pharmacies have been lost due to funding cuts.

American healthcare technology company Omnicell has appointed Edward Platt as the new Senior Commercial Director of its UK community pharmacy division. Along with this new role, Edward, who joined Omnicell in 2015, will continue his current leadership remit for Omnicell's UK & Ireland hospital division. He will be leading a revamped commercial team, which would be responsible for increasing Omnicell's footprint of automation and consumable solutions delivered into UK community pharmacies. As part of the revamp, the company has created dedicated specialist teams to ensure the needs and challenges of community pharmacists (small independents and small multiple operators) can be fully understood and supported.

The proposed increase in the national living wage (NLW) is expected to impose an implementation cost of £150 million to £195 million on the community pharmacy sector, Community Pharmacy England (CPE) has warned. Chancellor Jeremy Hunt recently announced a 9.8 per cent increase in the national living wage, raising it from £10.42 to £11.44. "The Autumn Statement overlooks the knock-on effects these measures will have on small businesses like community pharmacies," CPE Chief Executive Janet Morrison said in a statement. "The majority of pharmacies employ staff on or around the NLW, which has increased nearly 40 per cent since the start of the current contractual framework." "This is at a time when pharmacies have faced a 30 per cent real terms reduction in funding since 2015," Morrison added. "No viable business can absorb these cost increases without significant support. This is just another cost pressure that pharmacies cannot control and must be addressed through a sustainable, long-term funding arrangement."

The General Pharmaceutical Council (GPhC) has removed a pharmacist from its register who black-marketed 'zolpidem' along with another pharmacist between 2015 and 2016. Dean Zainool Dookhan, a pharmacist first registered with the Royal Pharmaceutical Society of Great Britain on 18 October 2004 and whose registration was later transferred to the General Pharmaceutical Council under registration number 2059808, was jailed last year for exporting 20,000 packets of zolpidem to the Caribbean. While hearing the case on 24-25 May, GPhC's Fitness to Practise Committee stated that "removal of the Registrant's name from the register is the appropriate and proportionate response to his convictions." "The public interest includes protecting the public, maintaining public confidence in the profession, and maintaining proper standards of behaviour. The Committee is entitled to give greater weight to the public interest than the Registrant's own interest in remaining on the register." "The Committee recognises the sanction has a punitive effect in that the Registrant's ability to practise and earn an income as a pharmacist and 28 his professional reputation will be curtailed; it will be five years before he can seek restoration to the register. However, that is the price he must pay for failing to comply with the fundamental tenets of his profession."

The National Institute for Health and Care Excellence (NICE) has recommended elosulfase alfa for routine use in the NHS for the treatment of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome). Elosulfase alfa, also called Vimizin and made by BioMarin, becomes the first disease modifying treatment recommended by NICE for routine NHS use for people with this rare, severely life-limiting condition. NICE's final draft guidance follows the collection of 'real-world' data from 69 people who received NHS-funded treatment since 2015 as part of a managed access agreement. Clinical trial evidence and data collected as part of the managed access agreement, along with expert clinical opinion, shows some long-term benefits with elosulfase alfa treatment which suggest it slows progression of MPS 4A.

Staveley Pharmacy, a well-established community pharmacy located in the picturesque village of Kendal within the Lake District, has undergone a change in ownership. The family-run business led by a husband-and-wife team has been acquired by brothers Mohammad Waqas and Khuram Shazad, taking the helm as first-time buyers, according to Hutchings Consultants. Known for its strong counter trade and deep community ties, the pharmacy has been nurtured and managed by the previous owners with a profound dedication to the local community. Over the years, they have developed the business into a trusted local institution. Paul Steet, Associate Director of Hutchings who managed the sale, reflected on the transition, noting the longstanding relationship with the sellers. "Having worked with the previous owners since 2015 when they initially contacted Hutchings Consultants to discuss a valuation of the business, I feel personally connected to this pharmacy. I am delighted that Mohammad and Khuram will be taking over the reins," he said.

"Not possible for pharmacists to check whether prescriptions issued from overseas registered prescribers have been issued in a similarly safe and effective way," the new Minister of State (Department of Health and Social Care) Karin Smyth said during a recent parliamentary written response. At a recent session on Monday, July 29th, at the House of Commons, MP Cat Smith raised an important question directed at the Secretary of State for Health and Social Care. Smith, who represents Lancaster and Wyre, and has been an MP continually since 7 May 2015, inquired about whether the Department of Health and Social Care had conducted a comparative assessment of the UK's stance on prescribing puberty blockers for treating gender incongruence in comparison to other European countries. Responding to the questions, MP Karin Smyth emphasised on the significance of the Cass Review and described it as one of the most thorough examinations conducted across the globe on gender identity services for children and young people.

Some people prefer herbal treatment to relieve the pain and itch of psoriasis. Here is complete information on the most popular do-it-yourself cure.

By using a combination of herbs for improving vision and herbs for supporting vision, you can greatly boost your overall eye health.

Despite the fact that protein is an important ingredient of the dietary regime, especially for the athletes who spendsizeable time pumping iron at the…

Girlfriend thinks she's coming out to support a comedy show and then gets a pleasant surprise as the final joke.

Suffering from wisdom teeth infection? Visit the Holistic dental clinic today to get right treatment for your teeth infection. Here you will get proper treatment and care at an affordable fee. Here dentists make sure that you get the right treatment it the proper care.